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Summary 3'P nuclear magnetic resonance (NMR) spectra of cells and of cell extracts revealed high levels of
phosphorylcholine (PC) and phosphocreatine (PCr) in an adriamycin-resistant human small cell lung car-
cinoma cell line (GLC4/ADR) and the adriamycin-sensitive parental cell line (GLC4). PCr levels in extracts of
GLC4/ADR were increased compared to extracts of GLC4. We estimated that 11% of the total intracellular
ATP is not bound to Mg2" in both cell lines. This value corresponded to an intracellular free Mg2" of
0.30 mM. The effects of different adriamycin concentrations, 0.05, 1 and 30 JLM for GLC4 and 1, 30 and 200 LM
for GLC4/ADR, on the phosphorus metabolite levels in continuously perfused cells were monitored.
Significant differences between GLC4 and GLC4/ADR included: (a) a strong increase in the PATP level in the
presence of 30 tLM adriamycin in GLC4 only, followed by a fast decrease after 5 h of perfusion. (b) a less
dramatic increase in the PC level in GLC4/ADR and an unchanged ATP level in the presence of increasing
adriamycin concentrations. (c) an increased GPC level in GLC4/ADR in the presence of adriamycin. The
changes in PC and GPC levels in the presence of adriamycin suggested that the phospholipid turnover was
increased in GLC4/ADR and could be stimulated in the presence of adriamycin. In both cell lines, PCr levels
decreased faster than the ATP levels after adriamycin treatment. Thus, biochemical markers for adriamycin
resistance can be detected with NMR spectroscopy. However, more studies are necessary to obtain parameters
to distinguish drug-sensitive from drug-resistant tumours in patients by NMR spectroscopy.
Changes in energy-metabolism may be involved in resistance.
Cell lines selected in vitro for resistance to adriamycin, Vinca
alkaloid or colchicine, exhibit the multidrug resistant (MDR)
phenotype. In these resistant cells a M, 170,000 kD P-
glycoprotein is overexpressed (Riordan & Ling, 1985; Pastan
& Gottesman, 1987). This P-glycoprotein functions as a
energy-dependent efflux pump to different types of
antitumour drugs (Riordan & Ling, 1985; Horio et al., 1988).
Increased free radical detoxification could also play a role in
adriamycin-resistance of these cells (Batist et al., 1986; Sinha
et al., 1987). Since both mechanisms are associated with
energy-dependent processes, expressing the MDR phenotype
may involve changes in energy requirements and energy
metabolism. These changes have actually been observed in an
adriamycin-resistant human breast cancer cell line (Cohen et
al., 1986; Yeh et al., 1987; Lyon et al., 1988). Cell lines
resistant to epipodophyllotoxins, ellipticine and m-AMSA
have also been established which do not overexpress the
P-glycoprotein (Glisson et al., 1986; Estey et al., 1987; Pom-
mier et al., 1986; Beck et al., 1987; Ferguson et al., 1988).
Cross resistance to other drugs is still observed and some-
times drug accumulation is decreased. It is unknown whether
this so-called atypical MDR (Beck et al., 1987) is accom-
panied by changes in energy requirements and energy
metabolism.
In order to obtain biochemical characteristics for the
atypical MDR phenotype we focussed on metabolites of both
energy metabolism (PCr, ATP and Pi) and phospholipid
metabolism (GPC, PE and PC) in an adriamycin-sensitive
small cell lung carcinoma cell line (GLC4) and an
adriamycin-resistant subline (GLC4/ADR), which exhibits the
atypical MDR phenotype (Zijlstra et al., 1987a; De Jong et
al., 1990). Phosphorus metabolite levels in living cells can be
monitored by 31P NMR spectroscopy. So far, studies on the
effect of adriamycin exposure on energy and lipid metabolism
using 31P NMR were only done in in vivo models of murine
mammary 16/C and murine mammary 17/C adenocar-
*This work was supported by the Dutch Cancer Foundation, Konin-
gin Wilhelmina Fonds, grant GUKC 86-01.
Correspondence: N.H. Mulder, Department of Internal Medicine,
University Hospital, Oostersingel 59, 9713 EZ Groningen, The
Netherlands.
Received 6 July 1990; and in revised form 1 October 1990.
cinomas (Evanochko et al., 1983; Evelhoch et al., 1987). In
vitro studies on cells using NMR spectroscopy necessitate
trapping a dense cell suspension in a small volume. We have
used the method described by Cohen et al. (1986) in which
cells were embedded in agarose gel threads (Foxall & Cohen,
1983; Knop et al., 1984). They have applied their technique
using 31P and 13C NMR spectroscopy to various cell lines
(Cohen et al., 1986; Lyon et al., 1988; Daly et al., 1987). In
their studies with small cell lung cancers the signal intensities
of PCR did not change relative to the ATP signal intensities
for over 24 h (Knop et al., 1987).
In the present study, 31P and 'H NMR spectroscopy was
employed to monitor levels of energy and phospholipid
metabolism in GLC4 and GLC4/ADR cells. The effect of
adriamycin on these levels were monitored in continuously
perfused cells using 31P NMR spectroscopy. The presence of
phosphorus metabolites characteristic for atypical MDR and
the presence of response-specific markers of adriamycin-
sensitivity and -resistance are discussed.
Materials and methods
Materials
RPMI 1640 medium was purchased from Gibco (Paisley,
Scotland). Dulbecco's Modified Eagles's medium (DME),
F12 medium and foetal calf serum (FCS) were obtained from
Flow Lab (Irvine, Scotland), low melting agarose from FMC
(Rockland, ME) and adriamycin from Farmitalia Carlo Erba
(Milano, Italy).
Cell lines
GLC4, a human small cell lung carcinoma cell line, was
derived from a pleural effusion in our laboratory and kept in
continuous culture in RPMI 1640 medium supplemented
with 10% FCS. GLC4/ADR, a subline of the parental line,
was made resistant by stepwise increasing concentrations of
adriamycin, until the cells were growing at a continuous drug
level of 1.I18IM. GLC4/ADR was 44-fold more resistant to
adriamycin than GLC4 after a I h exposure in the clonogenic
assay (Zijlstra et al., 1987a). GLC4/ADR exhibited cross-
resistance to several other drugs (Zijlstra et al., 1987a; De
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Jong et al., 1990; Meijer et al., 1987), while the P-
glycoprotein was not overexpressed in GLC4/ADR (De Jong
et al., 1990). Prior to experimental use, GLC4/ADR was
cultured without adriamycin for 20 days, at which time the
resistance factor was maximal (Meijer et al., 1987). Both cell
lines grow partly attached, partly floating and were cultured
in RPMI 1640 medium supplemented with 10% FCS at 37°C
in a humid atmosphere with 5% CO2.
Cellperfusion
Cells (1-1.5 x 108) were resuspended in DME/F12 medium
(pH 7.4) and 10% FCS. The perfusion system was prepared
as described previously (Foxall & Cohen, 1983; Knop et al.,
1984) with some modifications. Low-gelling agarose (0.8 ml
in 0.9% NaCI) was added at 37°C to 1.6 ml of a cell suspen-
sion. Agarose strands were extruded under light pressure
through a teflon capillary tube (0.5 mm inside diameter)
immersed in an ice/water bath into an Wilmad MRS tube
(1O mm inside diameter). The gel threads were perfused by
aspiration (1.4 ml min-'). A low perfusion rate was used in
this study, since the stability of the threads decreased in the
presence of adriamycin. Consequently, the number of cells
embedded in the threads had to be decreased to prevent
partial acidification of the cells. A number of layers of nylon
gauzes were used instead of a piece of sponge to restrain the
threads, resulting in a higher perfusion capacity. The per-
fusate from a 200 ml reservoir consisted of DME/F12 and
10% FCS supplemented with penicillin (125 U/ml[') and
streptomycin (125 U ml-'). Oxygen (95%) and CO2 (5%)
were bubbled through the perfusate in the reservoir.
Cell extracts
Cell extracts were made from 1-2 x 108 cells. The extraction
procedure was performed at 4°C. Ice-cold perchloric acid
(10%) was added to the pellet and the cell mixture was
vortexed at the beginning and the end of a 20 min period.
The extracts were neutralised with KOH, centrifuged to
remove the KC104 precipitate, freeze-dried and redissolved in
D20 (Evans & Kaplan, 1977).
'H and31P NMR spectroscopy
3'P NMR spectra (121.4 MHz) of perfused cells at 37°C were
obtained on a Varian VXR-300 spectrometer equipped with a
VXR 5000 data station. Spectra were usually obtained from
1500 transients with a spectral window of ± 4000 Hz, 4K
data points, a 650 pulse angle, a repetition rate of 2.25 s and
a line broadening of 20 Hz. All 31p chemical shifts in the
spectra were set relative to PCr by setting the PCr signal to
0.00 ppm.
'H NMR spectra of cell extracts were obtained from 1000
scans at 10°C with 90° pulse angle and a repetition time of
3.4 s under HDO decoupled conditions. 3'P NMR spectra of
cell extracts were obtained from 2000 scans at 10°C with a
550 pulse'angle and a repetition time of 40 s under proton
decoupled conditions. EDTA and diphenylphosphate were
added to a final concentration of 10 mM and 0.15 mM,
respectively.
Since the relative separations between the P and a, and the
and peaks of ATP are proportional to the amount of
ATP bound to Mg2+, the fraction of total ATP that is not
complexed to Mg2+ (0) can be calculated (Gupta & Moore,
1980a). The free Mg2+ concentration can then be calculated
using the dissociation constant of MgATP (ATP complexed
to magnesium) (Kd= 38 gM) and the formula [Mg2]= Kd
(0'-1 ) (Gupta & Moore, 1980a).
Spectra of perfused cells were obtained 3 h after the per-
fusion was started, when no major changes in the spectra
occurred. Two spectra were collected to estimate peak areas
and peak heights at t = 0. Peak intensities of the different
metabolites in spectra of cell extracts and in perfused cells
were estimated by peak areas determined from computer
simulated spectra using the deconvolution routine in the
VXR-5000 software. Changes in the levels of the phosphorus
metabolites in the presence or absence of adriamycin were
estimated from resolution-enhanced spectra by comparing
peak heights of the particular metabolite at different times.
Peak heights of a given metabolite were expressed as a
percent of the averaged peak height of this metabolite in the
two spectra at t = 0. At lower fields an underlying 'hump'
was absent in the spectra, which allowed the reliable and
reproducible measurement of peak intensities. Using peak
areas from resolution-enhanced spectra to estimate changes
in metabolites did not give significantly different results.
Statistics
All results were expressed as means ± s.d. Statistical
significance was determined by use of the Student's t-test.
Results
31P and 'H NMR spectra ofcell extracts
Cell extracts were made from adriamycin-sensitive (GLC4)
and adriamycin-resistant (GLC4/ADR) cells. Assignments
were made on basis of data in the literature (Daly et al.,
1987; Evans & Kaplan, 1977; Evanochko et al., 1984) and by
adding standard compounds. Extracts of both cell lines
showed high levels of PC (1 in Figure la and b). Additional
unidentified resonances could be seen, possibly AMP and PE,
on the low field side of the PC peaks. Low levels of probably
GPC (4) and GPE (3) could be detected in the extracts. High
levels of PCr (5) were detected in both cell lines with highest
PCr levels in the GLC4/ADR extracts (Table I). Expanding
the spectra revealed another triphosphate near the P
resonances of ATP (11) that accounted for 25 ± 4% (s.d.,
n = 3) of the total peak area in GLC4/ADR extracts and for
19 ± 4% in GLC4 extracts. This triphosphate could be UTP,
GTP or CTP (Evans & Kaplan, 1977; Evanochko et al.,
1984). High resolution 'H NMR spectra were obtained from
extracts of both cell lines in D20. Figure 2 shows the results
for GLC4. The identification of the peaks was made using
previous assignments in tumour cell extracts and by adding
standard compounds (Evanochko et al., 1984). The most
intense resonances originated from choline, PC, PCr and
creatine; furthermore, lactate, acetate and amino acids
(alanine, proline, glutamic acid and glutamine) were found.
In the low field region of the 'H NMR spectra resonances
from adenosine derivatives and some uracil-, guanine- and
cytosine-containing compounds predominated. No major
differences between spectra of GLC4 and GLC4/ADR were
found.
31P NMR spectra ofperfused cells
Spectra of perfused GLC4 and GLC4/ADR cells at 37°C were
recorded at a 2.25 s repetition rate and a 550 pulse angle to
ensure almost complete spin relaxation of the metabolites
(Figure 3). To estimate the relative levels of phosphorus
metabolites in GLC4 and GLC4/ADR we determined peak
areas of the various metabolites (Table II) in several spectra
at t = 0 by computer simulation of the spectra using a decon-
volution routine. Partially overlapping peaks could be
separated using this program. The peak areas were expressed
to that of the PATP (8) resonance. Peak areas of Pi (2) were
not used, since Pi was also present in the medium we used.
Peak area of 'yATP (5) was increased in GLC4/ADR com-
pared to GLC4. Since the peak areas are expressed relative to
the PATP peak area, the increased area of the yATP
resonance in GLC4/ADR must be due to some component
other than ATP. Comparing the extracts we concluded that
ADP was this component.
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Figure 1 31P NMR spectra (121.45 MHz) of the perchloric extracts of GLC4 a, and GLC4/ADR b. The pH (meter reading) was
7.8. Peak assignments are: 1, PC; 2, Pi; 3, GPE; 4, GPC; 5, PCr; 6, yATP; 7, PADP; 8, aATP; 9, aATP; 10, NAD; 11, PATP.
Table I Phosphorus metabolite levels in extracts of GLC4 and
GLC4/ADR (n = 3)
GLC4 GLC4/ADR
PC 1.83±0.44a 1.41 0.11
GPC 0.10±0.05 0.13±0.04
PCr 0.71 ±0.18 1.11 0.16d
yATPb 1.09 ± 0.14 1.20 0.07
aATPb 1.56 ± 0.11 1.66 0.12
PATPC 1.00 1.00
aPeak areas were obtained from spectra using a deconvolution
routine (see Materials and methods) and were expressed relatively to
the peak area of PATP (± s.d.), bADP, NAD and some other
triphosphates might be present, cSome other triphosphates might be
present, dp <0.025, GLC4 vs GLC4/ADR.
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Figure 2 'H NMR spectrum (300 MHz) of the perchloric extract
of GLC4/ADR. The pH was 7.4. The amplitude of the peaks in
the high field region (5.5-9.5 ppm) is eight times that of the
peaks in the low field region (0-4 ppm) A, adenine; G, guanine;
C, cytosine; U, uracyl; PCr, phosphocreatine; Cr, creatine;
PC + C, phosphorylcholine and choline; Pro, proline; Glu,
glutamic acid; Gln, glutamine; Ala, alanine; Lac, lactate.
Figure 3 31P NMR spectra (121.45 MHz) of perfused GLC4 a,
and GLC4/ADR b, cells at 37°C. Peak assignments are: 1, PC; 2,
Pi; 3, GPC; 4, PCr; 5, yATP; 6, xATP; 7, NAD; 8, PATP.
Table II Phosphorus metabolite levels in perfused GLC4 and
GLC4/ADR cells (n = 6)
GLC4 GLC4/ADR
PC 1.96 0.35 1.94 0.29
GPC 0.08 0.09 0.09 0.13
PCr 0.64±0.18 0.54±0.14
yATPb 1.03 0.15 1.27 0.2Id
aATPb 1.50± 0.26 1.76± 0.34
0ATPC 1.00 1.00
aPeak areas were obtained from spectra at t = 0 using a
deconvolution routine (see Materials and methods) and were
expressed relatively to the peak area ofPATP (± s.d.), bADP, NAD
and some other triphosphates might be present, cSome other
triphosphates might le present, dp <o.O5, GLC4 vs GLC4/ADR.
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Figure 4 Effect of different adriamycin concentrations on PCr
levels in perfused GLC4 a, and GLC4/ADR b, cells at 37°C. After
the 31P NMR spectra at t = 0 were obtained, adriamycin was
added to the perfusate. Levels were obtained from peak heights
of the metabolite in the 31P NMR spectra, as described in
Materials and methods, a, control ( O ), 0.05 JM
(-- --), I gM ( * ) and 30jM (--*--) adriamycin, b,
control ( 0 ), I gM ( M ), 30gLM (*-* -*) and
200gAM (** * ) adriamycin. Points, mean of three experiments,
bars, s.d.
catalysed by creatine kinase and adenylate kinase that are
important for energy metabolism (Lawson & Veech, 1979).
The spectra of perfused cells we had used to quantify relative
levels of metabolites were also used to estimate the fraction
of total ATP not bound to Mg2+. This fraction was
0.11 ± 0.01 in GLC4/ADR and 0.11 ± 0.02 in GLC4 cells.
The free intracellular Mg2+ concentrations were calculated
from these fractions as described in Materials and methods
and were 0.32 ± 0.03 mM and 0.30 ± 0.06 mM in GLC4/ADR
and GLC4. The total ADP concentration (MgADP and free
ADP) can be calculated from ATP, PCr and Cr concentra-
tions in extracts, the intracellular pH and the assumed
equilibrium constant KCk of the creatine kinase reaction at
this Mg2+ concentration according to Lawson et al. (1979).
The ATP concentration in extracts of both cell lines was
6 nmol/106 cells (De Jong et al., manuscript in preparation).
The Cr/PCr ratio was calculated from 'H NMR spectra of
extracts. For GLC4 and GLC4/ADR these ratios were
1.33 ± 0.12 (s.d., n = 3) and 1.39 ± 0.37, respectively. Assum-
ing that the intracellular and extracellular pH are equal
(pH 7.3), the calculated total ADP concentration was
t0.15 nmol/106 cells for GLC4 and GLC4/ADR.
Effect ofadriamycin on energy metabolite levels ofperfused
GLC4 and GLC4/ADR cells
Perfused cells were continuously exposed to 0.05gM, 1 JAM
and 30JAM adriamycin (GLC4) and to 1 JAM, 30JLM and
200 JAM adriamycin (GLC4/ADR) while the time course of the
phosphorus metabolite levels was followed. Each 3"P NMR
spectrum was obtained by accumulating 1500 scans which
took 1 h. Only significant changes are indicated.
PCr levels in the control (untreated GLC4 cells) increased
to 130% of the initial value (t=2-12h, P<0.05 vs t=0)
(Figure 4a). In the presence of 30 aM adriamycin, PCr levels
decreased rapidly after 4 h (t = 5-15 h, P <0.01 vs control)
and were almost undetectable at 15 h. In untreated GLC4/
ADR cells PCr levels did not increase significantly of the
initial value, while with a high concentration of adriamycin
(200jAM) PCr levels decreased after 4 h (t = 5-15 h,
P <0.005 vs control) and became undetectable after 13 h
(Figure 4b). The standard deviations of PCr levels were
rather large in adriamycin treated cells of both cell lines
because the peak intensity was low and therefore more
susceptible to noise.
Since the yATP and aATP resonances might contain some
contributions from ADP, changes in height of the J3ATP
resonance were used to determine the influence of adriamycin
on ATP. ATP levels in untreated GLC4 cells increased to
140% of the initial value (t=4-15h, P<0.05 vs t=0)
(Figure Sa). In the presence of 30JAM adriamycin an increase
to 175% of the initial ATP level was seen within 5 to 6 h
(t = 2-7 h, P <0.025 vs control), which subsequently
decreased to 20% at 15 h (Figure Sa and 6a). In untreated
GLC4/ADR cells ATP levels increased to 125% of the initial
value (t = 3-15 h, P <0.05 vs t = 0) (Figure Sb). With
200gM adriamycin ATP dropped to undetectable levels at
15 h (t = 6-15 h, P <0.01 vs control). Changes in yATP and
xATP intensities in untreated and adriamycin treated GLC4
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Figure 5 Effect of different adriamycin concentrations on PATP
levels in perfused GLC4 a, and GLC4/ADR b, cells at 37°C. After
the 31P NMR spectra at t = 0 h were obtained, adriamycin was
added to the perfusate. Levels were obtained from peak heights
of the metabolite in the 31P NMR spectra, as described in
Materials and methods. a, control ( 0 ), 0.5 JM
(----), 1 AM ( * ) and 30gM) (g*m ) adriamycin,
b, control ( 0 ), 1 M ( * ), 30gM (--*-)
and 200 JM ( **- ) adriamycin. Points, mean of three
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Figure 6 31P NMR spectra (121.45 MHz) of perfused GLC4 a, and GLC4/ADR, b, cells at different intervals in the presence of
30 JAm adriamycin. Adriamycin was added to the perfusate directly after the spectra at t = 0 h were obtained. Peak assignments are
as described in legend of Figure 3.
and GLC4/ADR cells were almost identical to changes in
PATP intensity (results not shown). Neither the percentage of
unbound ATP nor the intracellular Mg"~concentration
changed in the presence of various concentrations of
adriamycin.
The energy status of a cell could be described by the
PCr/IJATP ratio. We averaged the results from to 5 h, 6 to
h and to 15 h for the different adriamycin concentra-
tions used (Figure 7). From this figure it could be concluded
that the PCr level decreased faster than the I3ATP level in
both cell lines in response to high adriamycin concentrations,
30 JAm for GLC4 (t
= 5-15 h, P <0.01I vs control) and 200 JAm
for GLC4/ADR (t
= 10- 15 h, P <0.025 vs control). With
0.05 JAm adriamycin the PCr level decreased faster than the
PATP level in GLC4 cells (t
= 10- 15 h, P <0.05 vs control).
Effect of adriamycin on phospholipid metabolite levels of
perfused GLC4 and GLC4/ADR cells
PC levels in untreated GLC4 cells increased to 170% of the
initial value (t
= 2- 15 h, P <0.05 vs control) (Figure 8a). In
the presence of 30 JAm adriamycin the level slowly dropped to
40% of the initial value (t
= 5-15 h, P <0.005 vs control)
(Figures 6a and 8a). In untreated GLC4/ADR cells PC levels
increased to 150% (t
= 3 15 h, P <0.05 vs t =) (Figure 8b).
In the presence of increasing concentrations of adriamycin
PC levels increased less compared to levels in untreated cells
(30 J.m adriamycin, t =7-15 h, P <0.01 vs control) and
even decreased in the presence of 200 JM adriamycin
(t
= 3-15 h, P <0.025 vs control). The low intensity made
the level of GPC difficult to estimate; consequently the results
were averaged. Levels of GPC were expressed as percentage
of the initial peak height of I3ATP at 0 h, since GPC levels
were sometimes undetectable in the 0 h spectra. GPC peaks
were almost undetectable in GLC4 and did not change in the
presence of adriamycin (Figures 3a and 6a). GPC levels in
GLC4/ADR increased from 37 ± 9% (s.d.) in untreated cells
to 63 ± 17% (P <0.05 vs control) in I JAm adriamycin
treated cells and to 76 ± 29% (P <0.05 vs control) in 30 JAm
treated cells (Figures 3b and 6b). In the presence of 200 JAm
adriamycin GPC levels increased to 62 ± 6% (P <0.005 vs
control) and after 8 h decreased to control values.
Extracts of adriamycin treated cells
Extracts were made of cells treated with adriamycin to
examine the possibility that changes in components as
estimated in intact cells spectra were actually due to the
appearance of new components. After treatment of GLC4
cells and GLC4/ADR cells with and 30 JAm adriamycin for
h similar results were obtained in extracts as in perfused
cells, while no new components were detected in the spectra
(results not shown). Extracts were made from control GLC4
cells and from cells continuously incubated with 0.05 JAm and
I JAm adriamycin for 15 h. Two unassigned components,
probably PE and AMP, were clearly visible to the low field
of PC (1) in control GLC4 cell spectra (Figure 9a), that
disapppeared after treatment with JAm adriamycin (results
not shown). No new components were detected in extract
spectra of control GLC4/ADR cells (Figure 9b) and extract
spectra from cells after treatment with and 30 JAm
adriamycin for 15 h. 'H NMR spectra of these extracts
showed no changes at all in the presence of adriamycin
(results not shown).
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adriamycin was added to the perfusate. Ratios were obtained
from peak heights of the metabolites in the 31p NMR spectra, as
described in Materials and methods and Results.
PC was observed in cell extracts as well as intact cells
(Figures 1-3). The PE resonance was not present in the
spectra, since these cells were grown in media without
ethanolamine. However, these cells can still produce phos-
phatidylethanolamine by decarboxylation of phospha-
tidylserine (Daly et al., 1987; Ansell & Spanner, 1982). Phos-
pholipid analysis of our cell lines indeed revealed the
presence of phosphatidylethanolamine (Zijlstra et al., 1987b).
The presence of PC and PE in tumour cells might be of
diagnostic value, since in vivo human tumours showed
elevated levels of PC and PE compared to the tissue oforigin
(Daly & Cohen, 1989).
In adriamycin-resistant MCF-7 breast cancer cells, PCr
levels were increased, while PC, GPC, GPE and diphospho-
diester levels were decreased compared to the ATP level (in
the original report the PC and PE peaks were assigned to
sugar phosphates) (Cohen et al., 1986). NMR studies of
other cell lines indicated that differences observed in
metabolite levels did not correlate specifically with drug-
resistance (Evelhoch et al., 1987). Decreased GPC, PC and
PE levels were also observed in in vivo adriamycin-resistant
17/A adenocarcinomas, but as the untreated tumours pro-
gressed, the differences between the adriamycin-sensitive and
-resistant tumours disappeared (Evelhoch et al., 1987).
Therefore, it is uncertain whether differences in phosphorus
metabolite levels are related to the MDR or the atypical
MDR phenotype.
Both GLC4 and GLC4/ADR are anchorage-independent
cell lines. Since an increase in PC could be related to an
4- c.
Discussion
31P NMR spectra from perfused cells and extracts showed the
same resonances. Several cellular compartments have been
described such as mitochondria that might influence the peak
intensity of ,BATP (Gupta & Yushok, 1980b). However,
phosphorus metabolite content in cellular extracts as deter-
mined by "P NMR and biochemical analysis are in agree-
ment (Desmoulin et al., 1986). Furthermore, since spectral
resolution was enhanced and complete relaxation of the
phosphorus resonances spectra was obtained in our extracts,
the significance of differences observed in peak areas relative
to the PATP peak area is better indicated by comparing cell
extracts. The relative PCr concentration was higher in ex-
tracts of GLC4/ADR compared to GLC4, however the ratio
PCr/Cr was not changed. The percentage of unbound ATP
and the intracellular Mg2" concentration were similar in
intact GLC4 and GLC4/ADR cells. These results indicate that
the equilibrium constant for the creatine kinase reaction and
the equilibrium of this reaction are equal for both cell lines.
The calculated intracellular Mg"+ concentration of 0.3 mM
was comparable with the intracellular Mg"+ concentration of
0.4 mM in Ehrlich ascites tumour cells (Gupta & Yushok,
1980b). The relatively higher PCr level in GLC4/ADR could
increase the capacity of these cells to maintain the ATP pool.
In a previous report, high levels of PCr and low levels of
disphosphodiester were observed in variant SCLC cell lines
compared to classic SCLC cell lines (Knop et al., 1987).
Thus, the presence of high levels of PCr and the absence of
diphosphodiester support our earlier characterisation of these
two cell lines as variant SCLC cell lines (Zijlstra et al.,
1987a).
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Figure 8 Effect of different adriamycin concentrations on PC
levels in perfused GLC4 a, and GLC4/ADR b, cells at 37°C. After
the 31P NMR spectra at t = O h were obtained, adriamycin was
added to the perfusate. Levels were obtained from peak heights
of the metabolite in the 31P NMR spectra as described in
Materials and methods, a, control ( O ), 0.5pM
(----), 1 ILM ( * ) and 30iM ( -*- ) adriamycin,
b, control ( 0 ), 1 tLM ( * ), 30tum (--*-)
and 200tM (** * ) adriamycin. Points, mean of three
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Figure 9 31P NMR spectra (121.45 MHz) of the perchloric extracts of GLC4, a, and GLC4/ADR b, after 15 h. The pH was 7.8.
Peak assignments are as described in the legend of Figure 1.
increased cell growth (Daly et al., 1987), the significant in-
crease in PC and ATP in the control experiments with con-
tinuous perfused cells was probably due to cell growth. Fur-
thermore, the perfusion experiments showed that several
phosphorus metabolites were response-specific biochemical
markers of adriamycin sensitivity and resistance. When GLC4
cells were treated with 30g.M adriamycin ATP levels in-
creased faster than levels in untreated cells. This increase
could either be due to a decreased energy consumption or an
increased energy production. Even treatment with 200gM
adriamycin did not result in a strong increase of the ATP
level in GLC4/ADR, although the level dropped to undetect-
able during the experiment in a way similar to ATP levels in
GLC4 cells treated with 30gLM adriamycin. In both cell lines
the PCr/ATP ratio decreased in response to high adriamycin
concentrations. PCr was probably used to maintain the ATP
pool at a stable level via creatine kinase as described in
muscle (Bessman & Carpenter, 1985).
An interesting finding was the effect of adriamycin treat-
ment on the PC and GPC level only in GLC4/ADR cells. We
could not confirm the increase in GPC levels in extracts.
There are two possibilities. First, by using the continuous
perfusion system GLC4/ADR cells were physically stressed
resulting in an increase in phospholipid turnover that was
stimulated by adriamycin treatment. Secondly, the peak we
saw, was not due to GPC, but to a phospholipid component
also resulting from an increased phospholipid turnover. In
phospholipid synthesis, choline is converted to PC and fur-
ther converted to phosphatidylcholine (Ansell & Spanner,
1982). This phospholipid is degradaded to GPC and then to
choline by glycerophosphocholine phosphodiesterase (EC
3.1.4.2) (Ansell & Spanner, 1982; Morash et al., 1988). The
increased phospholipid turnover might be related to the
reduced adriamycin accumulation in GLC4/ADR cells. The
reduced drug accumulation was not due to the increased
activity of the P-glycoprotein (Zijlstra et al., 1987a; De Jong
et al., 1990).
In human and rat neuroectodermal tumours ATP levels
decreased strongly within 6 to 12 h after cyclophosphamide,
vincristine and methotrexate treatment, while PCr levels
remained undetactable (Naruse et al., 1985). In MOPC 104E
myeloma PCr/ATP ratio increased within 1 day after treat-
ment with a curative dose of cyclophosphamide or 1,3-bis(2-
chloroethyl)-l-nitrosourea, while PCr and ATP levels
strongly reduced within 4 days (Ng et al., 1982). In this study
it was concluded, that the changed PCr/ATP ratio must
partially reflect the effect of the chemotherapy on energy
metabolism within the tumour cells. ATP/Pi and PCr/Pi
ratios in adriamycin-sensitive mammary 17/A adenocar-
cinoma (Evelhoch et al., 1987), in the RIF-1 fibrosarcoma (Li
et al., 1988) and in GL gliosarcoma (Steen et al., 1988) were
increased after adriamycin, cyclophosphamide and 1,3-bis(2-
chloroethyl)-1-nitrosourea treatment, respectively. The in-
crease of these ratios after treatment was explained by
reenergization of the tumour, while untreated control
tumours in these studies showed declining ATP and PCr
levels (Evelhoch et al., 1987; Li et al., 1988; Steen et al.,
1988). Untreated neuroectodermal tumours were still in an
active stage which may explain the fast reduction in ATP
levels 3 h after treatment with cyclophosphamide (300 mg
kg-') (Naruse et al., 1985), while an opposite effect of cyclo-
phosphamide (300 mgkg-1) was seen in RIF-l fibrosarcoma
(Li et al., 1988). Untreated MOPC 104E myelomas were in a
moderate active stage which may explain the slow decrease in
ATP levels in 4 days (Ng et al., 1982).
In our in vitro experiments the continuous perfused cells
were supplied with sufficient nutrients. Therefore, these
results showed without any interference from reenergization
that adriamycin treatment had an effect on the energy
metabolism in the adriamycin-sensitive GLC4 tumour cells
which resulted in an increase of cellular ATP. The strong
decrease in ATP and PCr levels after treatment were com-
parable with the effects of chemotherapy in in vivo tumours
that were in a metabolic active stage (Ng et al., 1982; Naruse
et al., 1985). The same adriamycin concentration had no
effect on ATP and PCr levels in the adriamycin-resistant
GLC4/ADR tumour cells compared to untreated GLC4/ADR
cells. No differences in phosphorus metabolites were observed
in adriamycin treated and untreated adriamycin-resistant
mammary 17/A adenocarcinoma, while adriamycin had a
large effect on the adriamycin-sensitive tumour (Evelhoch et
al., 1987). To distinguish drug-sensitive from drug-resistant
tumours in patients, it will be necessary to compare changes
in phosphorus metabolite levels in tumours after treatment
with an estimation of the changes in nucleoside triphosphates
and PCr levels in this tumour that would occur without
chemotherapeutic treatment, since the metabolic stage of a
tumour probably determines the changes in phosphorus
metabolites after chemotherapy. To obtain a reliable esti-
mation, tissue heterogenity, tumour size, type of tumour, the
glycolytic rate of the tumour, tumour hypoxia and the degree
of vascularisation of a tumour have to be determined. Till
now only a few often preliminary data are available on
human tumour bioenergetics and responses to chemotherapy
observed by NMR (Steen, 1989). The continuous perfusion
system can be used to study the relation between hypoxia
and/or glucose deprivation and chemotherapeutic effectivity
in in vitro experiments.212 S. DE JONG et al.
In conclusion, 31P NMR spectroscopy can be used in in
vitro experiments to reveal biochemical markers for
adriamycin-resistance and -sensitivity. However, much more
in vitro and in vivo studies with drug-sensitive and drug-
resistant cells are necessary to obtain parameters to distin-
guish drug-sensitive from drug-resistant tumours in patients
after chemotherapy by NMR spectroscopy.
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